Table 3.
Summary of maraviroc pharmacokinetic parameters (study 2, cohort 1)
| Mean (CV% or SD) | |||
|---|---|---|---|
| Parameter | 3 mg i.v. (n = 8) | 10 mg i.v. (n = 8) | 30 mg i.v. (n = 8) |
| AUCt (ng ml−1 h)* | 57.6 (15.3%) | 201 (12.0%) | 670 (12.5%) |
| AUC (ng ml−1 h)* | nc | nc | 687 (12.0) |
| Cmax (ng ml−1)* | 36.9 (18.6%) | 122 (14.6%) | 397 (13.8%) |
| Tmax (h)† | 0.94 (0.12) | 0.94 (0.18) | 0.91 (0.19) |
| t1/2 (h)† | nc | nc | 13.2 (2.80) |
| CL (l h−1)† | nc | nc | 44.0 (5.55) |
| CLR (l h−1)† | 11.2 (1.52) | 10.5 (1.63) | 10.2 (1.69) |
| CLnR (l h−1)† | nc | nc | 33.8 (4.67) |
| Vss (l)† | nc | nc | 194 (60.7) |
*
Unadjusted geometric means (%CV).
†
Unadjusted arithmetic means (SD). CV, coefficient of variation; nc, not calculated; SD, standard deviation; Vss, volume of distribution at steady state.